Health Care Select, 72  Ticker: FPBPXX
 
Description
A unit investment trust that seeks above-average capital appreciation by investing in a concentrated portfolio of health care companies.
Please note that there is no assurance the objective will be met.
 
Summary
Product Code: HC2Y72
Portfolio Status: Secondary
Initial Offer Date: 10/13/2023
Secondary Date: 01/10/2024
Portfolio Ending Date: 10/14/2025
Tax Structure: Regulated Investment Company
Distributions: Semi-Annual
 
Initial Offer Price: $10.0000
NAV(*): $11.3628
POP(*): $11.6243
Remaining Deferred Sales Charge: $0.0000
* As of Trade Date: 10/04/2024 4:00pm ET
The Public Offering Price (POP) represents the net asset value per unit plus any applicable organization costs and sales charges. The Net Asset Value (NAV) represents the value per unit of a trust’s portfolio securities and other assets reduced by applicable deferred sales charges and other liabilities.

 Historical 12-Month Distribution of Trust Holdings:^
Rate (as of 10/4/2024) Per Unit (as of 9/30/2024)
1.11% $0.12890
^ There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The historical 12-month distribution per unit and historical 12-month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's distribution or distribution rate. The historical 12-month distribution per unit is based on the weighted average of the trailing twelve month distributions paid by the securities included in the portfolio. The historical 12-month distribution rate is calculated by dividing the historical 12-month distributions by the trust's offering price. The historical 12-month distribution and rate are reduced to account for the effects of fees and expenses, which will be incurred when investing in a trust. Certain of the issuers may have reduced their dividends or distributions over the prior twelve months. The distribution per unit and rate paid by the trust may be higher or lower than the amount shown above due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, or the sale of securities in the portfolio. For trusts that include funds, distributions may include realized short term capital gains, realized long-term capital gains and/or return of capital.

 Holdings Analysis Click here to Perform a Benchmark Comparison  
 Sector Weighting
Communication Services  Communication Services 0.00%
Consumer Discretionary  Consumer Discretionary 0.00%
Consumer Staples  Consumer Staples 0.00%
Energy  Energy 0.00%
Financials  Financials 0.00%
Health Care  Health Care 99.62%
Industrials  Industrials 0.00%
Information Technology  Information Technology 0.00%
Materials  Materials 0.00%
Real Estate  Real Estate 0.00%
Utilities  Utilities 0.00%
Other  Other 0.38%
 
  Large Mid Small  
Growth  62.39% 0.00% 0.00%  
Value  30.75% 6.48% 0.00%  

 Style Weighting
Large-Cap Growth 62.39%
Large-Cap Value 30.75%
Mid-Cap Growth 0.00%
Mid-Cap Value 6.48%
Small-Cap Growth 0.00%
Small-Cap Value 0.00%
Undetermined 0.38%
 Composition
U.S. Stocks 86.84%   Other 0.38%
Non-U.S. Stocks 12.78%      
The style and sector characteristics of the portfolio are determined as of 10/03/2024 and will likely vary thereafter due to market fluctuations in the underlying securities.  

 Key Stats
Weighted Average Market Cap $191,987
Price/Earnings 30.77
Price/Book 4.46
As of 10/3/2024
All market capitalization numbers are in USD$ Millions. All figures are subject to change.

 Holdings  Export Current Holdings | View Initial Holdings  
NameSymbolSectorStyleWeighting
 Boston Scientific Corporation BSX Health Care  Health Care Large-Cap Growth 4.92%
 HCA Healthcare, Inc. HCA Health Care  Health Care Large-Cap Value 4.72%
 Eli Lilly and Company LLY Health Care  Health Care Large-Cap Growth 4.26%
 Stryker Corporation SYK Health Care  Health Care Large-Cap Growth 3.89%
 GE HealthCare Technologies Inc. GEHC Health Care  Health Care Large-Cap Growth 3.85%
 AbbVie Inc. ABBV Health Care  Health Care Large-Cap Growth 3.76%
 Danaher Corporation DHR Health Care  Health Care Large-Cap Value 3.64%
 Abbott Laboratories ABT Health Care  Health Care Large-Cap Growth 3.56%
 Vertex Pharmaceuticals Incorporated VRTX Health Care  Health Care Large-Cap Growth 3.49%
 Thermo Fisher Scientific Inc. TMO Health Care  Health Care Large-Cap Growth 3.47%
 Regeneron Pharmaceuticals, Inc. REGN Health Care  Health Care Large-Cap Value 3.41%
 Cencora Inc. COR Health Care  Health Care Large-Cap Growth 3.40%
 ICON Plc ICLR Health Care  Health Care Mid-Cap Value 3.38%
 The Cigna Group CI Health Care  Health Care Large-Cap Value 3.27%
 Novo Nordisk A/S (ADR) NVO Health Care  Health Care Large-Cap Growth 3.26%
 AstraZeneca Plc (ADR) AZN Health Care  Health Care Large-Cap Growth 3.26%
 Amgen Inc. AMGN Health Care  Health Care Large-Cap Growth 3.21%
 UnitedHealth Group Incorporated UNH Health Care  Health Care Large-Cap Growth 3.13%
 Gilead Sciences, Inc. GILD Health Care  Health Care Large-Cap Growth 3.12%
 Zoetis Inc. ZTS Health Care  Health Care Large-Cap Growth 3.12%
 Elevance Health Inc. ELV Health Care  Health Care Large-Cap Value 3.11%
 Labcorp Holdings Inc. LH Health Care  Health Care Mid-Cap Value 3.10%
 Merck & Co., Inc. MRK Health Care  Health Care Large-Cap Growth 3.02%
 McKesson Corporation MCK Health Care  Health Care Large-Cap Value 3.01%
 Johnson & Johnson JNJ Health Care  Health Care Large-Cap Growth 2.93%
 Sanofi (ADR) SNY Health Care  Health Care Large-Cap Value 2.88%
 Centene Corporation CNC Health Care  Health Care Large-Cap Value 2.87%
 Bristol-Myers Squibb Company BMY Health Care  Health Care Large-Cap Growth 2.74%
 Pfizer Inc. PFE Health Care  Health Care Large-Cap Value 2.45%
 Humana Inc. HUM Health Care  Health Care Large-Cap Value 1.39%
 
Total Number of Holdings:    30
Underlying Securities information represented above is as of 10/03/2024 but will vary with future fluctuations in the market.

Risk Considerations

Equity Risk. An investment in a portfolio containing common stocks is subject to certain risks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

Sector Concentration Risk. A portfolio which is concentrated in an individual sector is subject to additional risks, including limited diversification.

Buy & Hold Risk – Taxable Trusts. This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

COVID-19 Economic Impact Risk. The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.

Foreign Securities Risk. Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

Health Care Risk. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

Large-Cap Risk. Large capitalization companies may grow at a slower rate than the overall market.

Market Disruption Risk. Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.

Mid-Cap Risk. An investment in a portfolio containing mid-cap companies is subject to additional risks, as the share prices of certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

Volatility Risk. The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

Operational Risk. As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

The style and capitalization characteristics used to describe the stocks are designed to help you understand how they fit into your overall investment plan. Due to changes in the value of the stocks the characteristics may vary over time. In general, growth stocks have high relative price-to-book ratios while value stocks have low relative price-to-book ratios. In determining market capitalization characteristics, we analyze the market capitalizations of the 3,000 largest stocks in the U.S. (excluding foreign securities, ADRs, limited partnerships and regulated investment companies) on a monthly basis. Companies with market capitalizations among the largest 10% are considered Large-Cap securities, the next 20% are considered Mid-Cap securities and the remaining securities are considered Small-Cap securities.

You should carefully consider the trust's investment objectives, risks, and charges and expenses before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

This product information does not constitute an offer to sell, or a solicitation of an offer to buy securities in any state to any person to whom it is not lawful to make such an offer. Sales of any of these securities must include prospectus delivery and the services of a retail broker/dealer duly licensed in the appropriate states.

Not FDIC Insured, Not Bank Guaranteed and May Lose Value.

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.